Basis of cell kill following clinical radiotherapy

Application of Apoptosis to Cancer Treatment

Volumn , Issue , 2005, Pages 293-320

  Faulhaber, Oliver ^a   Bristow, Robert G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

apoptosis; cell cycle arrest; ceramide; clonogenic survival; mitotic catastrophe; p53; radiobiology; radiotherapy; senescence; survivin

Indexed keywords

EID: 33645340920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-3302-8_13     Document Type: Chapter

References (154)

1. Ma, B.B., et al., Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol, 2003. 21(14): p. 2760-76.
2. Bristow, R.G. and R. Hill, Molecular and Celullar Basis of Radiotherapy. Basic Science of Oncology, 1998: p. McGraw Hill Publishers, New York.
3. Ward, J.F., Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res, 1995. 142(3): p. 362-8.
4. Kolesnick, R. and Z. Fuks, Radiation and ceramide-induced apoptosis. Oncogene, 2003. 22(37): p. 5897-906.
5. Morgan, W.F., et al., Genomic instability induced by ionizing radiation. Radiat Res, 1996. 146(3): p. 247-58.
6. Snyder, A.R. and W.F. Morgan, Gene expression profiling after irradiation: clues to understanding acute and persistent responses? Cancer Metastasis Rev, 2004. 23(3-4): p. 259-68.
7. Kim, I.A., et al., The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev, 2004. 23(3-4): p. 227-36.
8. Gupta, A.K., et al., Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res, 2002. 8(3): p. 885-92.
9. Harari, P.M. and S.M. Huang, Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys, 2004. 58(3): p. 976-83.
10. Hahn, S.M., et al., A Phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res, 2002. 8(5): p. 1065-72.
11. Pilch, D.R., et al., Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol, 2003. 81(3): p. 123-9.
12. Bakkenist, C.J. and M.B. Kastan, Initiating cellular stress responses. Cell, 2004. 118(1): p. 9-17.
13. Willers, H., J. Dahm-Daphi, and S.N. Powell, Repair of radiation damage to DNA. Br J Cancer, 2004. 90(7): p. 1297-301.
14. Rothkamm, K., et al., Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol, 2003. 23(16): p. 5706-15.
15. Olive, P.L. and J.P. Banath, Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys, 2004. 58(2): p. 331-5.
16. Lukas, J., C. Lukas, and J. Bartek, Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst), 2004. 3(8-9): p. 997-1007.
17. Dimri, G.P., et al., A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA, 1995. 92(20): p. 9363-7.
18. Cuddihy, A.R. and R.G. Bristow, The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev, 2004. 23(3-4): p. 237-57.
19. Roninson, I.B., Tumor cell senescence in cancer treatment. Cancer Res, 2003. 63(11): p. 2705-15.
20. Ponten, F., et al., Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. J Natl Cancer Inst, 2001. 93(2): p. 128-33.
21. Pawlik, T.M. and K. Keyomarsi, Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys, 2004. 59(4): p. 928-42.
22. Kao, G.D., W.G. McKenna, and T.J. Yen, Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene, 2001. 20(27): p. 3486-96.
23. Wilson, G.D., Radiation and the cell cycle, revisited. Cancer Metastasis Rev, 2004. 23(3-4): p. 209-25.
24. Bromfield, G.P., et al., Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis, 2003. 6(1): p. 73-85.
25. Brown, J.M. and B.G. Wouters, Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist Updat, 2001. 4(2): p. 135-6.
26. Abend, M., Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol, 2003. 79(12): p. 927-41.
27. Shankar, S., T.R. Singh, and R.K. Srivastava, Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate, 2004. 61(1): p. 35-49.
28. Abou El Hassan, M.A., et al., Overexpression of Bcl2 abrogates chemo-and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br J Cancer, 2004. 91(1): p. 171-7.
29. Marini, P. and C. Belka, Death receptor ligands: new strategies for combined treatment with ionizing radiation. Curr Med Chem Anti-Canc Agents, 2003. 3(5): p. 334-42.
30. Chauhan, D., et al., Cytochrome c-dependent and-independent induction of apoptosis in multiple myeloma cells. J Biol Chem, 1997. 272(48): p. 29995-7.
31. Yu, Y. and J.B. Little, p53 is involved in but not required for ionizing radiation-induced caspase-3 activation and apoptosis in human lymphoblast cell lines. Cancer Res, 1998. 58(19): p. 4277-81.
32. Herr, I. and K.M. Debatin, Cellular stress response and apoptosis in cancer therapy. Blood, 2001. 98(9): p. 2603-14.
33. Rudner, J., et al., Radiation sensitivity and apoptosis in human lymphoma cells. Int J Radiat Biol, 2001. 77(1): p. 1-11.
34. Mackey, T.J., et al., bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology, 1998. 52(6): p. 1085-90.
35. Matsumoto, H., et al., Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol, 2004. 34(3): p. 124-30.
36. Scopa, C.D., et al., bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol, 2001. 9(4): p. 329-34.
37. Wacheck, V., et al., Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer, 2003. 89(7): p. 1352-7.
38. Lowe, S.L., et al., Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther, 2001. 8(18): p. 1363-71.
39. Belka, C. and W. Budach, Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int J Radiat Biol, 2002. 78(8): p. 643-58.
40. Arafat, W.O., et al., An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int J Radiat Oncol Biol Phys, 2003. 55(4): p. 1037-50.
41. Yip, K.W., et al., Potential utility of bim(s) as a novel apoptotic therapeutic molecule. Mol Ther, 2004. 10(3): p. 533-44.
42. Belka, C., et al., Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys, 2004. 58(2): p. 542-54.
43. Wachsberger, P., R. Burd, and A.P. Dicker, Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res, 2003. 9(6): p. 1957-71.
44. Fridman, J.S. and S.W. Lowe, Control of apoptosis by p53. Oncogene, 2003. 22(56): p. 9030-40.
45. Slee, E.A., D.J. O'Connor, and X. Lu, To die or not to die: how does p53 decide? Oncogene, 2004. 23(16): p. 2809-18.
46. Fei, P., E.J. Bernhard, and W.S. El-Deiry, Tissue-specific induction of p53 targets in vivo. Cancer Res, 2002. 62(24): p. 7316-27.
47. Lowe, S.W., et al., p53 status and the efficacy of cancer therapy in vivo. Science, 1994. 266(5186): p. 807-10.
48. Gasco, M. and T. Crook, p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat, 2003. 6(6): p. 323-8.
49. Leo, C., A.J. Giaccia, and N.C. Denko, The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol, 2004. 14(3): p. 207-14.
50. Hammond, E.M. and A.J. Giaccia, The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst), 2004. 3(8-9): p. 1117-22.
51. Graeber, T.G., et al., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996. 379(6560): p. 88-91.
52. Geoerger, B., et al., Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer, 2003. 89(3): p. 577-84.
53. Nishizaki, M., et al., Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res, 2001. 7(9): p. 2887-97.
54. Swisher, S.G., et al., Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res, 2003. 9(1): p. 93-101.
55. Fang, B. and J.A. Roth, The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther, 2003. 5(5): p. 475-82.
56. Komarova, E.A., et al., Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene, 2004. 23(19): p. 3265-71.
57. Komarov, P.G., et al., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 1999. 285(5434): p. 1733-7.
58. Santana, P., et al., Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell, 1996. 86(2): p. 189-99.
59. Pena, L.A., Z. Fuks, and R.N. Kolesnick, Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res, 2000. 60(2): p. 321-7.
60. Paris, F., et al., Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001. 293(5528): p. 293-7.
61. Brown, M., et al., Comment on "Tumor response to radiotherapy regulated by endothelial cell apoptosis" (II). Science, 2003. 302(5652): p. 1894; author reply 1894.
62. Garcia-Barros, M., et al., Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science, 2003. 300(5622): p. 1155-9.
63. Hill, R.P., et al., Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys, 2001. 49(2): p. 353-65.
64. Aldridge, D.R., M.J. Arends, and I.R. Radford, Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. Br J Cancer, 1995. 71(3): p. 571-7.
65. Sheridan, M.T. and C.M. West, Ability to undergo apoptosis does not correlate with the intrinsic radiosensitivity (SF2) of human cervix tumor cell lines. Int J Radiat Oncol Biol Phys, 2001. 50(2): p. 503-9.
66. Pollack, A., et al., The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys, 2000. 46(1): p. 153-8.
67. Hintz, B.L., C. Koo, and J.F. Murphy, Pattern of proliferative index (Ki-67) after anti-androgen manipulation reflects the ability of irradiation to control prostate cancer. Am J Clin Oncol, 2004. 27(1): p. 85-8.
68. Musacchio, A. and K.G. Hardwick, The spindle checkpoint: structural insights into dynamic signalling. Nat Rev Mol Cell Biol, 2002. 3(10): p. 731-41.
69. Okada, H. and T.W. Mak, Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer, 2004. 4(8): p. 592-603.
70. Sudo, T., et al., Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells. Embo J, 2001. 20(22): p. 6499-508.
71. Roninson, I.B., Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat, 2002. 5(5): p. 204-8.
72. Jonathan, E.C., E.J. Bernhard, and W.G. McKenna, How does radiation kill cells? Curr Opin Chem Biol, 1999. 3(1): p. 77-83.
73. Elliott, M.J., et al., Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide. Cancer Chemother Pharmacol, 1999. 44(1): p. 1-11.
74. Castedo, M., et al., Cell death by mitotic catastrophe: a molecular definition. Oncogene, 2004. 23(16): p. 2825-37.
75. Nitta, M., et al., Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene, 2004. 23(39): p. 6548-58.
76. Altieri, D.C., Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 2003. 22(53): p. 8581-9.
77. Li, F., et al., Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998. 396(6711): p. 580-4.
78. Uren, A.G., et al., Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol, 2000. 10(21): p. 1319-28.
79. Carvalho, A., et al., Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci, 2003. 116(Pt 14): p. 2987-98.
80. Lu, B., et al., Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res, 2004. 64(8): p. 2840-5.
81. Mirza, A., et al., Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 2002. 21(17): p. 2613-22.
82. Hoffman, W.H., et al., Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem, 2002. 277(5): p. 3247-57.
83. Zhou, M., et al., DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther, 2002. 303(1): p. 124-31.
84. Adida, C., et al., Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol, 1998. 152(1): p. 43-9.
85. Asanuma, K., et al., A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res, 2002. 93(9): p. 1057-62.
86. Rodel, F., et al., High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 2002. 178(8): p. 426-35.
87. Rodel, C., et al., Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys, 2003. 55(5): p. 1341-7.
88. Grossman, D., et al., Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999. 113(6): p. 1076-81.
89. Pennati, M., et al., Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol, 2003. 120(4): p. 648-54.
90. Cao, C., et al., XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene, 2004.
91. O'Connor, D.S., et al., Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol, 2000. 156(2): p. 393-8.
92. Mesri, M., et al., Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol, 2001. 158(5): p. 1757-65.
93. Blanc-Brude, O.P., et al., Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res, 2003. 9(7): p. 2683-92.
94. Dixon, H. and C.J. Norbury, Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle, 2002. 1(6): p. 362-8.
95. Koniaras, K., et al., Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene, 2001. 20(51): p. 7453-63.
96. Hayflick, L. and P.S. Moorhead, The serial cultivation of human diploid cell strains. Exp Cell Res, 1961. 25: p. 585-621.
97. Campisi, J., From cells to organisms: can we learn about aging from cells in culture? Exp Gerontol, 2001. 36(4-6): p. 607-18.
98. Elenbaas, B. and R.A. Weinberg, Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res, 2001. 264(1): p. 169-84.
99. Sedelnikova, O.A., et al., Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol, 2004. 6(2): p. 168-70.
100. Wang, E., M.J. Lee, and S. Pandey, Control of fibroblast senescence and activation of programmed cell death. J Cell Biochem, 1994. 54(4): p. 432-9.
101. Spaulding, C., W. Guo, and R.B. Effros, Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol, 1999. 34(5): p. 633-44.
102. Harrington, L. and M.O. Robinson, Telomere dysfunction: multiple paths to the same end. Oncogene, 2002. 21(4): p. 592-7.
103. Guo, C., et al., Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol, 2001. 166(2): p. 694-8.
104. Orlando, C., et al., Telomerase in urological malignancy. J Urol, 2001. 166(2): p. 666-73.
105. Rubio, M.A., S.H. Kim, and J. Campisi, Reversible manipulation of telomerase expression and telomere length. Implications for the ionizing radiation response and replicative senescence of human cells. J Biol Chem, 2002. 277(32): p. 28609-17.
106. Pandita, T.K. and J.L. Roti Roti, Role of telomerase in radiocurability (review). Oncol Rep, 2003. 10(2): p. 263-70.
107. Pirzio, L.M., et al., Human fibroblasts expressing hTERT show remarkable karyotype stability even after exposure to ionizing radiation. Cytogenet Genome Res, 2004. 104(1-4): p. 87-94.
108. Bouffler, S.D., et al., Telomeric sequences, radiation sensitivity and genomic instability. Int J Radiat Biol, 2001. 77(10): p. 995-1005.
109. Goytisolo, F.A., et al., Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals. J Exp Med, 2000. 192(11): p. 1625-36.
110. Hauguel, T. and F. Bunz, Haploinsufficiency of hTERT leads to telomere dysfunction and radiosensitivity in human cancer cells. Cancer Biol Ther, 2003. 2(6): p. 679-84.
111. Wong, K.K., et al., Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet, 2000. 26(1): p. 85-8.
112. Kim, H.R., et al., Change of telomerase activity in rectal cancer with chemoradiation therapy. J Korean Med Sci, 2000. 15(2): p. 167-72.
113. Ogawa, Y., et al., Changes in telomerase activity of advanced cancers of oral cavity and oropharynx during radiation therapy: correlation with clinical outcome. Int J Mol Med, 1998. 2(3): p. 301-307.
114. Sawant, S.G., et al., Telomerase activity as a measure for monitoring radiocurability of tumor cells. Faseb J, 1999. 13(9): p. 1047-54.
115. Turriziani, M., et al., Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro. Anticancer Res, 2003. 23(6C): p. 4561-9.
116. Chang, B.D., et al., A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res, 1999. 59(15): p. 3761-7.
117. te Poele, R.H., et al., DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002. 62(6): p. 1876-83.
118. Wouters, B.G., et al., A p53 and apoptotic independent role for p21waf1 in tumour response to radiation therapy. Oncogene, 1999. 18(47): p. 6540-5.
119. Rodemann, H.P., et al., Selective enrichment and biochemical characterization of seven human skin fibroblasts cell types in vitro. Exp Cell Res, 1989. 180(1): p. 84-93.
120. Niggli, H.J., et al., Mitomycin C-induced postmitotic fibroblasts retain the capacity to repair pyrimidine photodimers formed after UV-irradiation. Mutat Res, 1989. 219(4): p. 231-40.
121. Di Leonardo, A., et al., DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev, 1994. 8(21): p. 2540-51.
122. Schmitt, C.A., et al., Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 2002. 1(3): p. 289-98.
123. Kim, J.H., J.H. Shin, and I.H. Kim, Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys, 2004. 59(4): p. 1174-80.
124. Biade, S., et al., Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol, 2001. 77(10): p. 1033-42.
125. Camphausen, K., et al., Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res, 2004. 64(1): p. 316-21.
126. Chung, Y.L., A.J. Wang, and L.F. Yao, Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther, 2004. 3(3): p. 317-25.
127. Chang, B.D., et al., Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA, 2000. 97(8): p. 4291-6.
128. Buffa, F.M., et al., Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res, 2004. 10(11): p. 3745-54.
129. Gewirtz, D.A., Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat, 2000. 62(3): p. 223-35.
130. Lera, J., et al., Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma: relation to the results of radiotherapy. Cancer, 1998. 83(12): p. 2493-501.
131. Li, R., et al., Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res, 2004. 10(12 Pt 1): p. 4118-24.
132. Pillai, M.R., P.G. Jayaprakash, and M.K. Nair, Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol, 1998. 124(8): p. 456-61.
133. Qureshi, K.N., et al., Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys, 2001. 51(5): p. 1234-40.
134. Rigaud, J., et al., Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate, 2004. 58(3): p. 269-76.
135. Santucci, M.A., et al., Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. Int J Radiat Oncol Biol Phys, 2000. 46(2): p. 411-6.
136. Sohda, M., et al., Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer, 2004. 110(6): p. 838-44.
137. Adell, G.C., et al., Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer, 2001. 91(10): p. 1870-5.
138. Chang, J., et al., Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer, 2000. 89(11): p. 2145-52.
139. Chung, E.J., et al., Spontaneous apoptosis as a predictor of radiotherapy in patients with stage IIB squamous cell carcinoma of the uterine cervix. Acta Oncol, 1999. 38(4): p. 449-54.
140. Gasinska, A., et al., A ratio of apoptosis to mitosis, proliferation pattern and prediction of radiotherapy response in cervical carcinoma. Neoplasma, 2002. 49(6): p. 379-86.
141. Kim, J.Y., et al., Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. Int J Cancer, 2001. 96(5): p. 305-12.
142. Langendijk, H., et al., Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol, 2000. 56(2): p. 197-207.
143. Lara, P.C., et al., Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Int J Radiat Oncol Biol Phys, 1999. 43(5): p. 1015-9.
144. Levine, E.L., et al., Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol, 1995. 37(1): p. 1-9.
145. Marijnen, C.A., et al., High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys, 2003. 57(2): p. 434-43.
146. Paxton, J.R., et al., Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy. J Clin Pathol, 2000. 53(3): p. 197-200.
147. Ravi, D., et al., Apoptosis, angiogenesis and proliferation: trifunctional measure of tumour response to radiotherapy for oral cancer. Oral Oncol, 2001. 37(2): p. 164-71.
148. Rodel, C., et al., Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys, 2000. 46(5): p. 1213-21.
149. Shears, L.L., et al., Apoptosis in esophageal cancer following induction chemoradiotherapy. J Surg Res, 1998. 79(1): p. 20-4.
150. Wheeler, J.A., et al., ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys, 1995. 32(5): p. 1487-93.
151. Shah, R. and W.S. El-Deiry, p53-Dependent Activation of a Molecular Beacon in Tumor Cells Following Exposure to Doxorubicin Chemotherapy. Cancer Biol Ther, 2004. 3(9).
152. Blasberg, R.G. and J.G. Tjuvajev, Molecular-genetic imaging: current and future perspectives. J Clin Invest, 2003. 111(11): p. 1620-9.
153. Haas, R.L., et al., In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys, 2004. 59(3): p. 782-7.
154. Lahorte, C.M., et al., Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging, 2004. 31(6): p. 887-919.